IX
ORIX Corporation
There isn't enough reported data to score IX yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
IX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| N/A | |
| N/A |
IX's profitability is currently strong. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like IX.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
IX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.8x | $34.08 | — |
| Cheap | 8.7x | $51.41 | +51% |
| Fair | 11x | $67.56 | +98% |
| Expensive | 14x | $82.03 | +141% |
Historical ranges are pointers, not guarantees.
IX has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
IX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong decline | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect IX's earnings and revenue to decline, with profitability weakening.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over IX on the outlook, with more favorable earnings and revenue expectations.
IX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $5.90 | +143% |
| Q1 2026 | $2.49 | +122% |
| Q1 2025 | $1.12 | +203% |
| Q1 2024 | $0.37 | +28% |
| Q4 2023 | $0.30 | -9.1% |
| Q3 2023 | $0.30 | 0% |
| Q1 2023 | $0.29 | -9.4% |
| Q4 2022 | $0.33 | +22% |
IX has the edge over MS in the latest year-over-year earnings comparison.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS's earnings per share have climbed steadily: $12.60 over the past year, up 29% from the year before, and higher year over year for 10 quarters in a row.
IX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.5B | +7% |
| Q1 2026 | $11.1B | +20% |
| Q3 2025 | $9.8B | +11% |
| Q1 2025 | $9.2B | -48% |
| Q3 2024 | $8.8B | +3.2% |
| Q1 2024 | $17.6B | +319% |
| Q4 2023 | $4.3B | +7.6% |
| Q3 2023 | $8.5B | -0.4% |
IX has the edge over MS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +0.3 points |
| Q1 2026 | 12% | -0.7 points |
| Q3 2025 | 16% | +1.3 points |
| Q1 2025 | 9.2% | -2.9 points |
| Q3 2024 | 14% | +2.6 points |
| Q1 2024 | 13% | -1.2 points |
| Q4 2023 | 14% | +3.3 points |
| Q3 2023 | 12% | +9 points |
IX's operating margin was 14% last quarter, about level with the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over IX on profitability, with a higher operating margin.
IX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +4.6% |
| Q1 2026 | $4.5B | +9.3% |
| Q3 2025 | $3.6B | +0.5% |
| Q1 2025 | $4.1B | -44% |
| Q3 2024 | $3.6B | +4.1% |
| Q1 2024 | $7.3B | +283% |
| Q4 2023 | $2B | +15% |
| Q3 2023 | $3.5B | +143% |
IX's free cash flow was $16B over the past year, down 2.2% from the year before. Free cash flow isn't a meaningful measure for financial services companies like IX.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
IX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -27M shares |
| 1 year | -81% | -4.7B shares |
| 3 years | -82% | -4.9B shares |
| 5 years | -83% | -5.3B shares |
| Available history | -83% | -5.4B shares |
IX has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $933.4M |
| Q1 2026 | $490.9M |
| Q3 2025 | $449.3M |
| Q1 2025 | $113.5M |
| Q3 2024 | $222M |
| Q1 2024 | $313.4M |
| Q4 2023 | $116.1M |
| Q3 2023 | $197.3M |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
IX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q3 2025 | 6.8x | High |
| Q1 2025 | 6.9x | High |
| Q1 2024 | 7.1x | High |
| Q4 2023 | 7.2x | High |
| Q3 2023 | 7.4x | High |
| Q1 2023 | 6.7x | High |
IX has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
IX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 11.3 | Oversold |
IX's weekly RSI is 38 (neutral) and its Stochastic is 11 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
IX PE vs Financial Services Sector
| Metric | IX | Sector median | Relative |
|---|---|---|---|
| PE | 5.8x | 13x | 56% below |
| PE % | 5 | 63 | 58 pts below |
IX has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
IX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.6 | 6.8% below |
| 20 week MA | $38.4 | 11% below |
| 50 week MA | $35.1 | 2.9% below |
| 100 week MA | $28.9 | 18% above |
| 200 week MA | $24.4 | 40% above |
IX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 40% above its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over IX on trend strength, trading above more of its moving averages.
IX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.6 | $14.8 | -11% |
| 2021 | $14.8 | $20.2 | +36% |
| 2022 | $20.2 | $16.3 | -19% |
| 2023 | $16.3 | $18.7 | +15% |
| 2024 | $18.7 | $21.4 | +15% |
| 2025 | $21.4 | $29.4 | +37% |
| 2026 YTD | $29.4 | $34.1 | +16% |
IX has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.